Literature DB >> 27064663

Different dosing regimens of repeated ketamine administration have opposite effects on novelty processing in rats.

Anett Schumacher1, Brindan Sivanandan1, Edgor Cole Tolledo1, Jacob Woldegabriel1, Rutsuko Ito2.   

Abstract

Repeated exposure to sub-anesthetic doses of ketamine in rats has been shown to induce cognitive deficits, as well as behavioral changes akin to the negative symptoms of schizophrenia, giving much face validity to the use of ketamine administration as a pharmacological model of schizophrenia. This study sought to further characterize the behavioral effects of two different ketamine pre-treatment regimens, focusing primarily on the effects of repeated ketamine administration on novelty processing, a capacity that is disrupted in schizophrenia. Rats received 5 or 14 intra-peritoneal injections of 30mg/kg ketamine or saline across 5 or 7days, respectively. They were then tested in an associative mismatch detection task to examine their ability to detect novel configurations of familiar audio-visual sequences. Furthermore, rats underwent a sequential novel object and novel object location exploration task. Subsequently, rats were also tested on the delayed matching to place T-maze task, sucrose preference task and locomotor tests involving administering a challenge dose of amphetamine (AMPH). The high-dose ketamine pre-treatment regimen elicited impairments in mismatch detection and working memory. In contrast, the low-dose ketamine pre-treatment regimen improved performance of novelty detection. In addition, low-dose ketamine pre-treated rats showed locomotor sensitization following an AMPH challenge, while the high-dose ketamine pre-treated rats showed an attenuated locomotor response to AMPH, compared to control rats. These findings demonstrate that different regimens of repeated ketamine administration induce alterations in novelty processing in opposite directions, and that differential neural adaptations occurring in the mesolimbic dopamine system may underlie these effects.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Animal model; Depression; Dopamine; Ketamine; Novelty detection; Schizophrenia

Mesh:

Substances:

Year:  2016        PMID: 27064663     DOI: 10.1016/j.pnpbp.2016.03.007

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  6 in total

1.  Ketamine-induced behavioural and brain oxidative changes in mice: an assessment of possible beneficial effects of zinc as mono- or adjunct therapy.

Authors:  Olakunle James Onaolapo; Olayemi Quyyom Ademakinwa; Temitayo Opeyemi Olalekan; Adejoke Yetunde Onaolapo
Journal:  Psychopharmacology (Berl)       Date:  2017-06-14       Impact factor: 4.530

2.  Comparative effects of sertraline, haloperidol or olanzapine treatments on ketamine-induced changes in mouse behaviours.

Authors:  O J Onaolapo; T B Paul; A Y Onaolapo
Journal:  Metab Brain Dis       Date:  2017-05-15       Impact factor: 3.584

3.  Long-lasting effects of repeated ketamine administration in adult and adolescent rats.

Authors:  M L Shawn Bates; Keith A Trujillo
Journal:  Behav Brain Res       Date:  2019-04-26       Impact factor: 3.332

Review 4.  Drug Abuse and Psychosis: New Insights into Drug-induced Psychosis.

Authors:  Suji Ham; Tae Kyoo Kim; Sooyoung Chung; Heh-In Im
Journal:  Exp Neurobiol       Date:  2017-02-07       Impact factor: 3.261

5.  Brain Changes Associated With Long-Term Ketamine Abuse, A Systematic Review.

Authors:  Jurriaan F M Strous; Cees J Weeland; Femke A van der Draai; Joost G Daams; Damiaan Denys; Anja Lok; Robert A Schoevers; Martijn Figee
Journal:  Front Neuroanat       Date:  2022-03-18       Impact factor: 3.856

6.  Ketamine and its metabolite, (2R,6R)-HNK, restore hippocampal LTP and long-term spatial memory in the Wistar-Kyoto rat model of depression.

Authors:  Lily R Aleksandrova; Yu Tian Wang; Anthony G Phillips
Journal:  Mol Brain       Date:  2020-06-16       Impact factor: 4.041

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.